Experts preview 6 breast cancer trials to watch at ESMO 2026, including KEYNOTE-B49, evERA, DESTINY-Breast11, SWITCH, PANKU-Breast01, and VIKTORIA-1.
News|Articles|October 22, 2026
ESMO 2026: The Presentations That May Transform The Lung Cancer Paradigm
Author(s)Russ Conroy
Fact checked by: Tim Cortese
ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in the lung cancer field.
Advertisement
Advertisement
At the
Related to this article
An expert highlights OrigAMI-4, iza-bren plus pembrolizumab, GORTEC IDEAL, and HexAgon-HN ahead of the ESMO Congress 2026.
At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
The acoustic coupling fluid is under substantive FDA review after a pivotal study of 44 patients reported improved ultrasound image quality during glioma surgery.
Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.
“What has changed is that we are bringing the phase 1 trials earlier in the course of treatment for our patients,” said Oana Danciu, MD.
Lisa Carter-Bawa, PhD, APRN, discusses policy barriers, arts-based outreach, AI, and stigma in lung cancer screening.
Advertisement
Advertisement